Histogen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
27 févr. 2023 16h15 HE
|
Histogen Inc
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments...
Histogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer
03 janv. 2023 16h05 HE
|
Histogen Inc
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments...
Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update
10 nov. 2022 16h15 HE
|
Histogen Inc
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and...
Histogen Announces Closing of $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
14 juil. 2022 16h05 HE
|
Histogen Inc
SAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase...
Histogen Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
12 juil. 2022 11h40 HE
|
Histogen Inc
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase...
Histogen Announces 1-for-20 Reverse Stock Split
01 juin 2022 16h00 HE
|
Histogen Inc
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase...
Histogen to Present at the H.C. Wainwright Global Investment Conference
17 mai 2022 16h05 HE
|
Histogen Inc
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase...
Histogen Reports First Quarter 2022 Financial Results and Provides Business Update
12 mai 2022 16h05 HE
|
Histogen Inc
Received $3.75 Million Payment from Allergan Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoing with Top-Line Data Anticipated in the First Half of 2023 SAN DIEGO, May ...
Histogen to Report First Quarter 2022 Financial Results and Provide Business Update
28 avr. 2022 16h05 HE
|
Histogen Inc
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase...
Histogen Announces Closing of $4.75 Million Private Placement
25 mars 2022 16h05 HE
|
Histogen Inc
SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body’s...